文献速递主动脉疾病

EVAR术后Ib型内漏:发生率、管理策略与结局的系统综述与Meta分析

Type Ib Endoleak after Endovascular Aortic Repair: Occurrence Rate, Management Strategies, and Outcomes. A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-07-29

最常采用的治疗方式为髂总动脉远端支架延长(40.9%)、延伸至髂外动脉联合髂内动脉栓塞(25.9%)、髂分支支架(16.3%)和晚期开放转换(14.5%);总体技术成功率和临床成功率分别为96.4%和95.5%,早期死亡率为3.4%。结论认为腔内治疗是最常采用的方式且技术成功率高。

要点

  • EVAR术后Ib型内漏估计发生率为3.7%,诊断距EVAR加权平均约39.8个月。
  • 最常用治疗为髂总动脉远端支架延长(40.9%),总体技术成功率96.4%。
  • 总体临床成功率95.5%,早期死亡率3.4%,随访期复发率3.3%。

核心结论

  • 现有证据表明腔内治疗是EVAR术后Ib型内漏最常采用的方式,且与高技术成功率相关。

研究设计与样本

  • 遵循PRISMA指南的系统综述与Meta分析(PROSPERO注册号CRD420261304103),检索MedLine、Web of Science、Scopus和Cochrane Library。
  • 采用随机效应模型进行比例Meta分析,主要结局为技术成功、临床成功和早期死亡率(≤30天)。

主要发现

  • Ib型内漏估计发生率为3.7%(95%CI 2.9-4.5),EVAR至诊断的加权平均时间为39.8个月(95%CI 33.1-46.5)。
  • 最常采用的治疗方式为髂总动脉远端支架延长(40.9%;95%CI 23.6-58.2;技术成功率96.0%)。
  • 其他方式包括延伸至髂外动脉联合髂内动脉栓塞(25.9%;95%CI 15.5-36.4;技术成功率92.5%)、髂分支支架(16.3%;95%CI 2.5-30.2;技术成功率96.6%)和晚期开放转换(14.5%;95%CI 7.3-21.7;技术成功率90.1%)。
  • 总体技术成功率和临床成功率分别为96.4%(95%CI 94.4%-98.5%)和95.5%(95%CI 93%-98%)。
  • 估计术中死亡率为3.2%(95%CI 1.3-5.2),早期死亡率为3.4%(95%CI 1.5-5.4),随访期(平均35.8个月)Ib型内漏复发率为3.3%(95%CI 1.3-5.4)。

临床怎么用

  • 对于EVAR术后随访发现的Ib型内漏,可优先考虑腔内治疗,最常用方式为髂总动脉远端支架延长。
  • 选择延伸至髂外动脉时需联合髂内动脉栓塞,髂分支支架和晚期开放转换可作为备选策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the available evidence on the management and outcomes of type Ib endoleak (TIbEL) after endovascular aortic repair (EVAR). METHODS: A systematic literature search (MedLine, Web of Science, Scopus, and Cochrane Library) was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO registration number: CRD420261304103). Studies reporting at least 5 cases of TIbEL after EVAR were included. Primary outcomes were technical success (TS), clinical success (CS), and early mortality (≤30 days). Meta-analyses of proportions were performed using a random-effects model. RESULTS: Thirty-seven studies including 474 patients with 516 TIbEL were analyzed. The estimated occurrence rate of TIbEL was 3.7% (95% CI 2.9-4.5). The weighted mean time from EVAR to TIbEL diagnosis was 39.8 months (95% CI 33.1-46.5). The most frequently adopted treatment approaches were distal stent-graft extension in the common iliac artery (40.9%; 95% CI 23.6-58.2; TS 96.0%), stent-graft extension to the external iliac artery with internal iliac artery embolization (25.9%; 95% CI 15.5-36.4; TS 92.5%), iliac branch endograft (16.3%; 95% CI 2.5-30.2; TS 96.6%), and late open conversion (14.5%; 95% CI 7.3-21.7; TS 90.1%). Overall TS and CS rates were 96.4% (95% CI 94.4% to 98.5%) and 95.5% (95% CI 93% to 98%), respectively. The estimated intraoperative mortality was 3.2% (95% CI 1.3-5.2), while early mortality was 3.4% (95% CI 1.5-5.4). The estimated recurrence rate of TIbEL during follow-up (mean 35.8 months) was 3.3% (95% CI 1.3-5.4). CONCLUSION: The available evidence indicates that endovascular treatment is the most commonly adopted approach and is associated with high TS.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cicala N, Di Leo A, Bianchini Massoni C, et al. Type Ib Endoleak after Endovascular Aortic Repair: Occurrence Rate, Management Strategies, and Outcomes. A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42526749. doi:10.1016/j.avsg.2026.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。